Methods of treating skin disorders using an anti-il-31ra antibody

Abstract

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

What is claimed is: 
     
         1 . A method of treating a patient with a skin disorder selected from the group consisting of:
 a) prurigo nodularis;   b) Cutaneous T cell Lymphoma;   c) Bullous pemphigoid;   d) Vitiligo;   e) Acne Rosacea; and   f) Scleroderma;   wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising an anti-Interleukin-31RA (IL-31RA) antibody or an antigen-binding fragment thereof and a pharmaceutically acceptable carrier to the patient, wherein the anti-IL-31RA antibody or antigen-binding fragment binds amino acid residues 20-519 of SEQ ID NO:6.   
     
     
         2 . The method of  claim 1 , wherein the anti-IL-31RA antibody or antigen-binding fragment is neutralizing. 
     
     
         3 . The method of  claim 1 , wherein the Fc region of the anti-IL-31RA antibody is IgG, IgA, IgD, IgM or IgE. 
     
     
         4 . The method of  claim 1 , wherein the Fc region of the anti-IL-31RA antibody is IgG. 
     
     
         5 . The method of  claim 1 , wherein the anti-IL-31RA antibody or an antigen-binding fragment thereof is humanized.